The researches based this research on the cases of women with preeclampsia (PE). It reduced uterine perfusion pressure (RUPP) pre-clinical rat model of PE have elevated angiotensin II type 1 receptor agonistic autoantibodies (AT1-AA) and cerebrovascular dysfunction.

This study was done to test the hypothesis that the angiotensin II type 1 receptor autoantibody blockade improves cerebral blood flow autoregulation and hypertension in a preclinical model of preeclampsia.

Sprague Dawley rats were observed to be having RUPP surgery with/without AT1-AA inhibitor (‘n7AAc’144 μg/day) osmotic minipumps. The main focus variables were the mean arterial pressure (MAP), CBF autoregulation, blood-brain barrier (BBB) permeability, cerebral edema, oxidative stress, and eNOS carefully assessed to come to clinically useful findings that shall aid future interventions.

‘n7AAc’ improved MAP, restored CBF autoregulation, prevented cerebral edema, elevated oxidative stress, and increased phosphorylated eNOS protein in RUPP rats.

The study concluded that inhibiting the AT1-AA in ischemic placental rats prevents hypertension, cerebrovascular dysfunction, and improves cerebral metabolic function.

Reference: https://www.tandfonline.com/doi/full/10.1080/10641955.2020.1833215